Abstract 9P
Background
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare subtype of liver cancer that primarily affects young adults and is characterized by a distinct histological appearance. Despite its rarity, FL-HCC has a worse prognosis compared to more common forms of liver cancer, and there is a significant lack of understanding of the epidemiology and risk factors associated with this disease. This study aims to investigate the epidemiology and risk factors of FL-HCC using the Surveillance, Epidemiology, and End Results (SEER) database.
Methods
The study used SEER database (2000-2019) to extract cases of FL-HCC and data on demographics, tumours and treatment. Demographic, tumour and treatment information was collected for each case. Data on age, sex, race, and other demographic factors for the general population was also extracted. Survival analysis using Kaplan-Meier and Cox proportional hazards was conducted to investigate the associations between demographic factors and FL-HCC survival rate. Analysis was done using Statistical Package for the Social Sciences (SPSS) 27.
Results
Three hundred thirty-eight patients were included, with Males 210 (62.1%) and white race 266 (78.7%) as the majority. Surgery was performed in 173 (51.2%) patients. At the end of the study period, 220 (65.1%) had died, and the median (IQR) survival rate of all study populations was 24 (7 - 59.3) months. Participants who underwent surgery had a median survival of 50 (24 - 88.5) months compared to those without surgery, with a median survival of 10 (2 - 22.5). The survival distributions for surgery were statistically significantly different, χ2(2) = 118.228, p < 0.001. Only younger age and performance of surgery had a significant effect on survival per Cox proportional hazard model, while sex and race had no significant effect on survival.
Conclusions
The results of this study provide a comprehensive overview of the epidemiology and survival factors of FL-HCC. However, additional studies would be required to identify risk factors for patients with this type of cancer, which would aid in developing new prevention and treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.